Survival analysis of the randomized phase II trial to investigate androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.

02/06/2022

Fernando Cotait Maluf, Andrey Soares, Diogo Assed Bastos, Fabio A. B. Schutz, Eduardo Cronemberger, Murilo Luz, Suelen P. S. Martins, David Queiroz Borges Muniz, Flavio Mavignier Carcano, Oren Smaletz, Fábio A Peixoto, Andrea J Gomes, Felipe Melo Cruz, Fabio Franke, Daniel Herchenhorn, Rosemarie Gidekel, Taiane Francieli Rebelatto, Rafaela Gomes, Vinicius Carrera Souza, Andre P. Fay

DOI: 10.1200/JCO.2022.40.16

Full link: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.1002

Survival analysis of the randomized phase II trial to investigate androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.

Send us a message

Cura Project

Survival analysis of the randomized phase II trial to investigate androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415.

Related Posts

In reply to Li et al. Letter to the editor. “Once daily (OD) versus twice-daily (BID) chemoradiation for limited stage small cell lung cancer (LS-SCLC): A meta-analysis of randomized clinical trials.”

Moderately hypofractionated post-operative radiation therapy for breast cancer: Preferences amongst radiation oncologists from countries in Latin America and the Caribbean

TP040/#1418 Palbociclib plus letrozole combination after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube or peritoneal cancer (LACOG 1018

Subgroup analysis of Brazilian participants of a medical leadership competencies instrument: a cross-sectional survey study of the Latin American Cooperative Oncology Group (LACOG) and the Academy of Leadership Sciences Switzerland (ALSS)